Evidence map›Paper›PMID 39075115›Full record

ArticleNPJ precision oncology2024

Peptide-stimulated T cells bypass immune checkpoint inhibitor resistance and eliminate autologous microsatellite instable colorectal cancer cells.

Sandra Schwarz, Zhaoran Su, Mathias Krohn, Markus W Löffler, Andreas Schlosser, Michael Linnebacher

Abstract read
In one paragraph

Article in NPJ precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sandra SchwarzDepartment of General Surgery, Molecular Oncology and Immunotherapy, University Medicine Rostock, Rostock, Germany.ORCID http://orcid.org/0000-0002-8112-4392
Zhaoran SuDepartment of General Surgery, Molecular Oncology and Immunotherapy, University Medicine Rostock, Rostock, Germany.
Mathias KrohnDepartment of General Surgery, Molecular Oncology and Immunotherapy, University Medicine Rostock, Rostock, Germany.
Markus W LöfflerDepartment of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0003-2513-1317
Andreas SchlosserRudolf-Virchow Center, Center for Integrative and Translational Bioimaging, University of Würzburg, Würzburg, Germany.
Michael LinnebacherDepartment of General Surgery, Molecular Oncology and Immunotherapy, University Medicine Rostock, Rostock, Germany. michael.linnebacher@med.uni-rostock.de.ORCID http://orcid.org/0000-0001-8054-1402

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two hypermutated colon cancer cases with patient-derived cell lines, peripheral and tumor-infiltrating T cells available were selected for detailed investigation of immunological response.T cells co-cultured with autologous tumor cells showed only low levels of pro-inflammatory cytokines and failed at tumor recognition. Similarly, treatment of co-cultures with immune checkpoint inhibitors (ICI) did not boost antitumor immune responses. Since proteinase inhibitor 9 (PI-9) was detected in tumor cells, a specific inhibitor (PI-9i) was used in addition to ICI in T cell cytotoxicity testing. However, only pre-stimulation with tumor-specific peptides (cryptic and neoantigenic) significantly increased recognition and elimination of tumor cells by T cells independently of ICI or PI-9i.We showed, that ICI resistant tumor cells can be targeted by tumor-primed T cells and also demonstrated the superiority of tumor-naïve peripheral blood T cells compared to highly exhausted tumor-infiltrating T cells. Future precision immunotherapeutic approaches should include multimodal strategies to successfully induce durable anti-tumor immune responses.

Identifiers

PMID39075115
PMCPMC11286882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.